Farrar Lab Alumni

The Farrar Lab

Graduate Students and Post Doctoral Fellows in the lab are working on research that is focused in three broad areas: B-cell development in the bone marrow and B-cell acute lymphoblastic leukemia (ALL), the developmental pathway of T regulatory cells, and cancer immunotherapy.

View publications here.

Looking for current Farrar Lab Info or Graduate Students, Post Doctoral Fellows or Research Associates?  click here


Graduate Students

Matthew Burchill, Ph.D.

burchillProgram: MICaB
Defense Year:2007
Advisor:Mike Farrar
Dissertation Title: "Interleukin-2 Receptor Dependant STAT5 Activation Drives Regulatory T Cell Development."

Current PositionAssistant Professor, Department of Medicine, Division of Gastroenterology and Hepatology, University of Colorado, Denver, CO.
Contact Info:Matthew.Burchill@ucdenver.edu 

Christine Goetz, Ph.D.

goetzProgram: MICaB
Defense Year:2005
Advisor:Mike Farrar
Dissertation Title: "Regulation of B Lymphocyte Development and Lineage Commitment by the Ras and STAT5 Signaling Pathways."

Current Position: Scientist 1, R&D Systems, Minneapolis, MN
Contact InfoChristine.Goetz@bio-techne.com


Casey Katerndahl, Ph.D.

caseyProgram MICaB
Defense Year: 2015
Advisor: Mike Farrar
Dissertation Title: "The Balance of STAT5 and NFkB or IKAROS at Enhancer Networks Dictates Progenitor B cell Survival, Proliferation, and Differentiation."

Current Position: Instructor, Department of Medicine in the Division of Oncology, Washington University in St. Louis
Contact Infokate0007@umn.edu 

Lin-Xi Li, Ph.D.

lin li

Program: MCDB&G  
Defense Year: 2009
Advisor:Mike Farrar
Dissertation Title: "Regulation of early B and T cell development by RAS and STAT5 signaling pathways."

Current PositionAssistant Professor, University of Arkansas for Medical Sciences
Contact InfoLXLI@UAMS.EDU 

David Owen, Ph.D.

David OwenProgram: MCDB&G  
Defense Year: 2020
Advisor:Mike Farrar
Dissertation Title: "Development of Regulatory T Cells Capable of Maintaining Immune Homeostasis."

Current PositionPost Doctoral Fellow, Farrar Lab, University of Minnesota
Contact Infoowenx190@umn.edu


Shawn Mahmud, M.D, Ph.D


Program: MICaB
Defense Year:2014
Advisor:Mike Farrar
Dissertation Title: "TNF Receptor Superfamily Costimulation Drives Thymic Treg Development and Repertoire Selection."

Current PositionPediatric Resident, University of Minnesota
Contact Infomahmu004@umn.edu 


Luke Manlove, Ph.D.

lukeProgram: MCDB&G
Defense Year:2015
Advisor:Mike Farrar
Dissertation Title: "Anti-leukemia Immunity is Enabled by Unmasking Cross Reactive Antigens with Vaccination and Checkpoint Blockade."

Current Position: Research Scientist I, Gilead Sciences, Seattle, WA
Contact Infomanl0039@umn.edu 

Laura Ramsey, Ph.D.


Program: MCDB&G
Defense Year:2009
Advisor:Mike Farrar
Dissertation Title: "B Cell Receptor Signaling in Receptor Editing and Leukemia."

Current Position: Assistant Professor, Cincinnati Children's Hospital
Contact Infolaura.ramsey@cchmc.org 

Kieng Bao Vang-Dings, Ph.D.

kieng vangProgram: MICaB
Defense Year:2010
Advisor:Mike Farrar
Dissertation Title: "Co-Stimulation and IL2 in Natural Regulatory T cell Development."

Current Position: Research Assistant Professor, University of Arkansas-Little Rock
Contact Infokbvangdings@ualr.edu  
very small link


Mark Willette, Ph.D.

markProgram: MICaB
Defense Year:2010
Advisor:Mike Farrar
Dissertation Title: "The Role of STAT5 in Early B cell Development and Leukemia"

Current Position:Instructor, University of Wisconsin-Stout
Contact Infowillettem@uwstout.edu


Jianying Yang, M.D., Ph.D.

yangProgram: MICaB
Defense Year:2009
Advisor:Mike Farrar
Dissertation Title: "The Role of the IL-2R Beta-Mediated Cytokine Signaling in Natural Regulatory T Cell Development."

Current Position:Internist, Mount Auburn Associates, Cambridge, MA
Contact Info(617) 868-2650 (Office)


Post Doctoral Fellows

Can Hekim, Ph.D.

Can Hekim

Fellowship dates: 2017-2019
Research Emphasis
Study of Leukemia antigen specific CD4 T cells, how they become toleragenic during Leukemia progression and how we can revert this so they can eradicate the tumor cells.

Current Position:  Senior Scientist at Orion Pharma Oyj, Turku, Finland
Contact Info:  can.hekim@gmail.com



Katherine Vrieze, Ph.D.


Fellowship dates: 2011-2014
Research Emphasis
:  Investigated the immune response to BCR-ABL induced leukemias and studied the response in the presence of nilotinib, a tyrosine kinase inhibitor, currently used to treat human ALL and CML patients to determine how TKI treatment affects the CD4 T-cell immune response to BCR-ABL induced leukemia.

Current Position: Medical Science Liaison at Incyte, St. Paul, MN